MEK114375: A Rollover Study to Provide Continued Treatment with GSK1120212 to Subjects with Solid Tumors or Leukemia

Phase 2

Completed

• Conditions: non-small cell lung cancer; lung cancer; 10029107

• Registration Number: NL-OMON38447
• Lead Sponsor: GlaxoSmithKline

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 1

Inclusion Criteria

• Currently participating in trametinib study and is receiving treatment with trametinib.
• Currently receiving clinical benefit as determined by the investigator from previous treatment with trametinib either as monotherapy or as part of a combination treatment regimen.

Exclusion Criteria

• Local access to commercially available GSK1120212.
• Current use of a prohibitive medication(s) as listed in the protocol (section 6.2).
• Bazett-corrected interval >=501 msec at the time of transition to this study.
• LVEF < institutional lower limit of normal.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>None.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>None.</p><br>